FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-02								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Burnett Patrick					2. Issuer Name and Ticker or Trading Symbol Arcutis Biotherapeutics, Inc. [ARQT]									ck all applica Director Officer (able)	g Pers	on(s) to Issu 10% Ow Other (s	ner	
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year)								┤ ^	below) below)					
C/O ARCUTIS BIOTHERAPEUTICS, INC.					08/03/2020							See Remarks							
2945 TO	WNSGATE	E ROAD SUITE	110																
(Street) WESTLA	C	A	91361		4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Cline) X Form filed by One Reporti Form filed by More than Cleron								rting Person						
(City)	(S	itate)	(Zip)																
		Та	ble I - Non-	Derivat	ive S	ecuritie	s Acc	quired,	Dis	posed c	of, or B	enef	icially	Owned					
Date				2. Transact Date (Month/Day	Execution Date,		Date,	Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			5. Amoun Securities Beneficia Owned Fo	s Fo ally (D) following (I)		: Direct I r Indirect E str. 4) (7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) (D)	or	Price	Transacti (Instr. 3 a	on(s)			iiisti. 4)	
Common Stock 08/03				08/03/2	3/2020			A		33,500	0(1)	A	\$ <mark>0</mark>	33,5	500 ⁽²⁾		D		
			Table II - D			curities Is, warr	•	,	•		,		•	Owned		,			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	Transaction Code (Instr.		re l	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisabl		xpiration ate	Title	or Nur	ount mber Shares		Transacti (Instr. 4)	on(s)			
Stock Option (Right to Buy)	\$25.89	08/03/2020		A		320,000		(3)	0	8/03/2030	Common Stock	32	0,000	\$0.00	320,00	00	D		

Explanation of Responses:

- 1. Grant of Restricted Stock Units ("RSU"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
- 2. Includes 33,500 RSUs. The RSUs will begin vesting upon the achievement of the performance-based milestones.
- 3. The option vests as to 1/4 of the total shares on August 1, 2021, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vested on August 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

Senior Vice President and Chief Medical Officer

/s/ John W. Smither, as

Attorney-in-Fact for Patrick 08/05/2020

Burnett

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.